Cargando…
Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias
Hereditary coproporphyria (HCP) and variegate porphyria (VP) are referred to as neurocutaneous porphyrias (NCP). Data concerning their systemic presentation are limited and no direct attempt of comparison of the two has ever been made. Our aim was to describe the type and frequency of systemic manif...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811049/ https://www.ncbi.nlm.nih.gov/pubmed/33489763 http://dx.doi.org/10.1016/j.ymgmr.2021.100707 |
_version_ | 1783637429277687808 |
---|---|
author | Kaftory, Ran Edel, Yonatan Snast, Igor Lapidoth, Moshe Mamet, Rivka Elis, Avishay Hodak, Emmilia Levi, Assi |
author_facet | Kaftory, Ran Edel, Yonatan Snast, Igor Lapidoth, Moshe Mamet, Rivka Elis, Avishay Hodak, Emmilia Levi, Assi |
author_sort | Kaftory, Ran |
collection | PubMed |
description | Hereditary coproporphyria (HCP) and variegate porphyria (VP) are referred to as neurocutaneous porphyrias (NCP). Data concerning their systemic presentation are limited and no direct attempt of comparison of the two has ever been made. Our aim was to describe the type and frequency of systemic manifestations of NCPs in Israeli patients. A cross-sectional survey was conducted. The study population included all patients with NCP diagnosed at the Israeli National Service for Biochemical Diagnoses of Porphyrias (INSP) between 1988 and 2019. Of the 83 patients with NCP who were alive in 2019, 61 (73%) completed the survey, 40 with VP and 21 with HCP. Systemic symptoms were reported by 63% of the VP group and 62% of the HCP group (p = .96); corresponding rates of cutaneous symptoms were 58% and 5% (p < .001). We found no association between the occurrence of systemic and cutaneous symptoms. Among patients with systemic involvement, abdominal pain was the predominant systemic symptom, found in 64% of the VP group and 69% of the HCP group; Analysis of symptom frequency showed that in 68% of the VP group, systemic symptoms (either abdominal, musculoskeletal or neuropsychiatric) occurred on a daily/weekly basis, whereas the HCP group experienced less than one symptom per week (p < .001). This nationwide study depicts a significantly heavier disease burden in VP patients compared to HCP owing to its more frequent neurovisceral and cutaneous manifestations. |
format | Online Article Text |
id | pubmed-7811049 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-78110492021-01-22 Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias Kaftory, Ran Edel, Yonatan Snast, Igor Lapidoth, Moshe Mamet, Rivka Elis, Avishay Hodak, Emmilia Levi, Assi Mol Genet Metab Rep Research Paper Hereditary coproporphyria (HCP) and variegate porphyria (VP) are referred to as neurocutaneous porphyrias (NCP). Data concerning their systemic presentation are limited and no direct attempt of comparison of the two has ever been made. Our aim was to describe the type and frequency of systemic manifestations of NCPs in Israeli patients. A cross-sectional survey was conducted. The study population included all patients with NCP diagnosed at the Israeli National Service for Biochemical Diagnoses of Porphyrias (INSP) between 1988 and 2019. Of the 83 patients with NCP who were alive in 2019, 61 (73%) completed the survey, 40 with VP and 21 with HCP. Systemic symptoms were reported by 63% of the VP group and 62% of the HCP group (p = .96); corresponding rates of cutaneous symptoms were 58% and 5% (p < .001). We found no association between the occurrence of systemic and cutaneous symptoms. Among patients with systemic involvement, abdominal pain was the predominant systemic symptom, found in 64% of the VP group and 69% of the HCP group; Analysis of symptom frequency showed that in 68% of the VP group, systemic symptoms (either abdominal, musculoskeletal or neuropsychiatric) occurred on a daily/weekly basis, whereas the HCP group experienced less than one symptom per week (p < .001). This nationwide study depicts a significantly heavier disease burden in VP patients compared to HCP owing to its more frequent neurovisceral and cutaneous manifestations. Elsevier 2021-01-13 /pmc/articles/PMC7811049/ /pubmed/33489763 http://dx.doi.org/10.1016/j.ymgmr.2021.100707 Text en © 2021 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Kaftory, Ran Edel, Yonatan Snast, Igor Lapidoth, Moshe Mamet, Rivka Elis, Avishay Hodak, Emmilia Levi, Assi Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias |
title | Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias |
title_full | Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias |
title_fullStr | Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias |
title_full_unstemmed | Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias |
title_short | Greater disease burden of variegate porphyria than hereditary coproporphyria: An Israeli nationwide study of neurocutaneous porphyrias |
title_sort | greater disease burden of variegate porphyria than hereditary coproporphyria: an israeli nationwide study of neurocutaneous porphyrias |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811049/ https://www.ncbi.nlm.nih.gov/pubmed/33489763 http://dx.doi.org/10.1016/j.ymgmr.2021.100707 |
work_keys_str_mv | AT kaftoryran greaterdiseaseburdenofvariegateporphyriathanhereditarycoproporphyriaanisraelinationwidestudyofneurocutaneousporphyrias AT edelyonatan greaterdiseaseburdenofvariegateporphyriathanhereditarycoproporphyriaanisraelinationwidestudyofneurocutaneousporphyrias AT snastigor greaterdiseaseburdenofvariegateporphyriathanhereditarycoproporphyriaanisraelinationwidestudyofneurocutaneousporphyrias AT lapidothmoshe greaterdiseaseburdenofvariegateporphyriathanhereditarycoproporphyriaanisraelinationwidestudyofneurocutaneousporphyrias AT mametrivka greaterdiseaseburdenofvariegateporphyriathanhereditarycoproporphyriaanisraelinationwidestudyofneurocutaneousporphyrias AT elisavishay greaterdiseaseburdenofvariegateporphyriathanhereditarycoproporphyriaanisraelinationwidestudyofneurocutaneousporphyrias AT hodakemmilia greaterdiseaseburdenofvariegateporphyriathanhereditarycoproporphyriaanisraelinationwidestudyofneurocutaneousporphyrias AT leviassi greaterdiseaseburdenofvariegateporphyriathanhereditarycoproporphyriaanisraelinationwidestudyofneurocutaneousporphyrias |